Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
Follow VTRS
Viatris Inc. (VTRS) EV/FCF
As of 16 October 2026, Viatris Inc. (VTRS) trades at a EV/FCF of 18.1×. Over the past ten years it has ranged from 5.7× (March 2025) to 171× (July 2015); the current reading is higher than 48% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 14.3× | 111.64% |
| FY2024 | 6.7× | (38.65%) |
| FY2023 | 11.0× | (11.21%) |
| FY2022 | 12.4× | (19.30%) |
| FY2021 | 15.3× | (78.12%) |
| FY2020 | 70.1× | 323.96% |
| FY2019 | 16.5× | (29.51%) |
| FY2018 | 23.5× | (23.92%) |
| FY2017 | 30.8× | 11.17% |
| FY2016 | 27.7× | (0.24%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 16.4× | 0.08% |
| Mar 2026 | 16.4× | 14.60% |
| Dec 2025 | 14.3× | (12.87%) |
| Sep 2025 | 16.4× | 122.75% |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | 12.1× |
| HLN Haleon PLC Sponsored ADR compare | 12.4× |
| NBIX Neurocrine Biosciences, Inc. compare | 15.9× |
| ZTS Zoetis Inc. compare | 18.0× |
| VTRS Viatris Inc. | 18.1× |
| UTHR United Therapeutics Corporation compare | 18.7× |
| ELAN Elanco Animal Health Incorporated compare | 42.4× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 43.8× |
| RDY Dr. Reddy's Laboratories Ltd compare | 72.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement